TCM
TCG Crossover Management Portfolio holdings
AUM
$876M
This Quarter Return
+42.58%
1 Year Return
+23.66%
3 Year Return
+996.72%
5 Year Return
–
10 Year Return
–
AUM
$1.26B
AUM Growth
+$1.26B
(+40%)
Cap. Flow
+$278M
Cap. Flow
% of AUM
21.99%
Top 10 Holdings %
Top 10 Hldgs %
58.32%
Holding
38
New
9
Increased
5
Reduced
7
Closed
5
Top Buys
| 1 |
CG Oncology
CGON
|
$157M |
| 2 |
Astria Therapeutics
ATXS
|
$74.3M |
| 3 |
Keros Therapeutics
KROS
|
$58.2M |
| 4 |
Ocular Therapeutix
OCUL
|
$48.4M |
| 5 |
Edgewise Therapeutics
EWTX
|
$41.5M |
Top Sells
| 1 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$58.4M |
| 2 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$54.1M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$45.3M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$26.5M |
| 5 |
Structure Therapeutics
GPCR
|
$21.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$2.04B
| $157M | 12.39% | +3,570,206 | New | +$157M |
|
2
Dyne Therapeutics
DYN
$1.92B
| $75.2M | 5.95% | 2,650,150 +1,000,000 | +61% | +$28.4M |
|
|
3
Astria Therapeutics
ATXS
$349M
| $74.3M | 5.87% | +5,278,928 | New | +$74.3M |
|
|
SLN
4
Silence Therapeutics
SLN
$227M
| $71.2M | 5.63% | 3,295,350 +1,190,475 | +57% | +$25.7M |
|
|
5
Structure Therapeutics
GPCR
$1.11B
| $68.5M | 5.42% | 1,598,421 -511,163 | -24% | -$21.9M |
|
|
JBIO
6
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $65.1M | 5.15% | 2,201,274 | – | – |
|
|
INBX
7
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $61.2M | 4.84% | 1,750,387 | – | – |
|
|
8
Keros Therapeutics
KROS
$618M
| $58.2M | 4.6% | +879,344 | New | +$58.2M |
|
9
Geron
GERN
$893M
| $57.4M | 4.54% | 17,391,639 -5,984,200 | -26% | -$19.7M |
|
10
Savara
SVRA
$567M
| $49.8M | 3.94% | 10,000,000 | – | – |
|
|
11
Ocular Therapeutix
OCUL
$2.12B
| $48.4M | 3.83% | +5,319,148 | New | +$48.4M |
|
12
Cogent Biosciences
COGT
$1.69B
| $41.8M | 3.3% | 6,214,375 +583,333 | +10% | +$3.92M |
|
|
13
Edgewise Therapeutics
EWTX
$1.51B
| $41.5M | 3.28% | +2,272,728 | New | +$41.5M |
|
14
Mineralys Therapeutics
MLYS
$1.03B
| $41.1M | 3.25% | +3,185,185 | New | +$41.1M |
|
15
Madrigal Pharmaceuticals
MDGL
$9.76B
| $39.9M | 3.15% | 149,283 -30,634 | -17% | -$8.18M |
|
16
Tourmaline Bio
TRML
$601M
| $33.8M | 2.68% | 1,477,593 +469,691 | +47% | +$10.8M |
|
17
Tyra Biosciences
TYRA
$675M
| $32.6M | 2.58% | 1,989,103 | – | – |
|
|
CMPS
18
Compass Pathways
CMPS
$424M
| $32.1M | 2.54% | 3,858,000 | – | – |
|
19
Kura Oncology
KURA
$686M
| $30.4M | 2.4% | 1,423,642 | – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.47B
| $28.9M | 2.28% | 793,829 -349,028 | -31% | -$12.7M |
|
21
Adverum Biotechnologies
ADVM
$64.6M
| $28.4M | 2.25% | +2,008,340 | New | +$28.4M |
|
22
Soleno Therapeutics
SLNO
$3.6B
| $23.5M | 1.86% | +550,000 | New | +$23.5M |
|
|
CNTA
23
Centessa Pharmaceuticals
CNTA
$2.25B
| $23.1M | 1.82% | 2,040,816 | – | – |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $15.7M | 1.24% | 1,100,000 | – | – |
|
25
VistaGen Therapeutics
VTGN
$102M
| $14.1M | 1.12% | 2,676,580 | – | – |
|